Hypertrophy, Left Ventricular
21
0
1
16
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
4.8%
1 terminated out of 21 trials
94.1%
+7.6% vs benchmark
33%
7 trials in Phase 3/4
13%
2 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (21)
CMR T1 Mapping for Diagnosis of Cardiac Amyloidosis
Towards Understanding the Phenotype of Cardiovascular Disease in CKD - TRUE-Type-CKD Study
Early Valve Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic Patients With Severe AS
Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure
Effect of a Targeted Notification and Clinical Support Pathway on Individuals With Left Ventricular Hypertrophy
Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study
Predictors of Left Ventricular Hypertrophy in Hypertensive Patients in Assiut Governorate
Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants
Effects of a Reduction in Renal Function on Cardiovascular Structure and Function
EMPower: Electronic Media Powering Positive Health Changes in Youth
Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension?
Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH
The CLEVER Study - Coreg And Left Ventricular Mass Regression
Cardiac MR of Subclinical CVD: Impact of Age
Racial Differences in the Coronary Microcirculation
New-onset Diabetes and Left Ventricular Hypertrophy in Renal Transplantation
The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5
Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy
Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant
Glutamate and Diastolic Function in Patients Undergoing Aortic Valve Repair